COVID-19
Conditions
Brief summary
Data about the links between Coronavirus disease 2019(COVID-19) and the safety of blood products during the pandemic is inadequate. During the COVID-19 pandemic, high volumes of patients receiving blood products due to post-terminal surgical complications depleted stores for the entire hospital, resulting in surgeons unable to acquire emergent blood products. Data from this study can be used to develop a policy on how to handle blood shortage issues during this and future pandemics. Also, this data can be used to determine future policies on use of blood products from COVID-19-positive donors.
Detailed description
* To identify the circumstances associated with observed delays in receiving blood products to use in emergent cases. * Determine the cost/benefit of moribund patients receiving massive transfusion during the COVID-19 pandemic. * Quantify COVID-19 diagnosis and complications in patients arriving with no indication of disease at index admission as relative to in hospital or blood product exposure.
Interventions
The COVID-19 pandemic is contributing to delays in blood product acquisition and inadequate blood product supplies for emergent cases in hospitals
Sponsors
Study design
Eligibility
Inclusion criteria
\>\_18 years of age Surgical patients treated at Methodist Dallas Medical Center(MDMC)
Exclusion criteria
\<18 years of age Prisoners Pregnant women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time frame | 1 year | Dates of inadequate or delayed blood products for emergent cases during the timeframe of the COVID-19 pandemic (March 2020 to March 2021) to be compared relative to number of days or cases where no shortages were noted |
Countries
United States
Contacts
Methodist Health System